Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Liabilities and Shareholders Equity (2018 - 2025)

Neurogene's Liabilities and Shareholders Equity history spans 6 years, with the latest figure at $288.6 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 14.04% year-over-year to $288.6 million; the TTM value through Dec 2025 reached $1.2 billion, up 35.89%, while the annual FY2025 figure was $288.6 million, 14.04% down from the prior year.
  • Liabilities and Shareholders Equity reached $288.6 million in Q4 2025 per NGNE's latest filing, roughly flat from $287.8 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $335.7 million in Q4 2024 to a low of $89.6 million in Q3 2023.
  • Average Liabilities and Shareholders Equity over 3 years is $214.1 million, with a median of $209.0 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 98.41% in 2024, then decreased 14.04% in 2025.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $222.6 million in 2023, then surged by 50.84% to $335.7 million in 2024, then decreased by 14.04% to $288.6 million in 2025.
  • Per Business Quant, the three most recent readings for NGNE's Liabilities and Shareholders Equity are $288.6 million (Q4 2025), $287.8 million (Q3 2025), and $297.3 million (Q2 2025).